表皮生长因子受体 - 氨酸激酶抑制剂 (EGFR-TKI) 的肝毒性
Lulin Zhu1, Xinxin Yang2, Shanshan Wu2
1Department of Pharmacy, Key Laboratory of Clinical CancerPharmacology andToxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
皮肤生长因子受体氨酸激酶抑制剂 (EGFR-TKIs) 的肝毒性是癌症患者的一个重大问题. 本综述探讨了EGFR-TKI肝损伤机制,临床特征和管理策略.
科学领域:
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物诱导性肝损伤 (DILI) 是一种常见的不良反应.
- 癌症患者面临肝功能障碍的风险增加,复杂化抗癌药物使用.
- 皮肤上生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 在治疗固体瘤方面至关重要,但可以引起显著的肝毒性.
研究的目的:
- 审查与EGFR-TKI相关的肝毒性临床特征和发病率.
- 探索了解EGFR-TKI诱导的肝损伤机制的最新进展.
- 讨论重新挑战和治疗策略来管理EGFR-TKI肝毒性.
主要方法:
- 对EGFR-TKI肝毒性临床研究和研究的文献综述.
- 报告的临床特征和发病率的分析.
- 综合当前关于机制,临床管理和治疗策略的知识.
主要成果:
- EGFR-TKIs与增加肝毒性有关,限制了它们的临床应用.
- 肝损伤的机制是复杂的,通过抑制DNA合成直接损害肝细胞是已知的因素之一.
- 除了直接毒性之外的具体机制在很大程度上仍然不清楚,有效的解决方案有限.
结论:
- 肝毒性是癌症患者EGFR-TKI治疗中的一个关键挑战.
- 对EGFR-TKI诱导的肝损伤机制的进一步研究是必不可少的.
- 开发有效的管理和治疗策略对于安全的临床应用至关重要.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
相关概念视频
Mitogens and the Cell Cycle
Clinical Applications of Epidermal Stem Cells
Receptor Tyrosine Kinases
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
